REGULATORY

• Regulatory Reform Panel Calls for Review of Clinical Trial Ad Rules
  May 30, 2025

• Ishin Nixes Ruling Bloc’s Draft Social Security Plans over OTC-Like Drug Issue
  May 30, 2025

• LDP Pharma Study Group’s Final Proposal Urges Raising of Social Security Budget Ceiling
  May 29, 2025

• LDP Fiscal Reform HQ’s Proposal Keeps Budget Ceiling Intact, but Urges Action on Wage Front
  May 28, 2025

• Tap Consumption Tax Revenue to Ensure Stable Generic Supply: LDP League
  May 28, 2025

• LDP Group Renews Call for Addition of MCI Screening to Health Checkups
  May 28, 2025

• MOF Panel Again Presses for Expansion of CEA Scheme: “Spring” Proposal
  May 27, 2025

• Honebuto Outline Includes “Raise in Official Prices,” but Details Yet Unknown
  May 27, 2025

• Japan Govt Plans Consortium for Driving Domestic Production of Radioisotopes
  May 27, 2025

• Topic of OTC-Like Drugs Dropped from 3-Party Talks: Ishin
  May 27, 2025

• MSD’s Welireg, BMS’ Inrebic, J&J’s Talvey Up for Japan Panel Review on June 6
  May 26, 2025

• Impact of Nationwide Implementation of Regional Formularies “Difficult to Estimate”: MHLW Official
  May 23, 2025

• Pfizer’s UC Drug, MSD’s PAH Therapy, and More Up for Panel Review on June 4
  May 22, 2025

• MHLW Orders Label Revisions for Diuretics, Zolgensma
  May 22, 2025

• LDP Generic League Calls for Necessary Pricing Steps to Ensure Quality and Supply
  May 22, 2025

• MHLW Working Group Begins Discussions to Update List of “Stable Supply Medicines”
  May 22, 2025

• OTC-Like Drug Is Hardest Topic in Tripartite Social Security Talks: Japan PM
  May 22, 2025

• LDP Commission Mulls Proposal for Price Revisions That Enable Wage Hikes on Par with Other Industries
  May 21, 2025

• LDP’s Pharmaceutical Security League Reboots under New Chair
  May 21, 2025

• MHLW Seeks Development Sponsors for 5 “Drug Loss” Products
  May 21, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• …
• Next ›
• 最終 »